La vendita allo scoperto per OptimizeRx dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di OptimizeRx. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

OptimizeRx (NASDAQ:OPRX) Azioni, Report sulle vendite allo scoperto

OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

OptimizeRx Corp

<h3>Gainers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) shares moved upwards by 33.8% to $6.69 during Thursday's pre-market session. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 18.3% to $0.39. The company's market cap stands at $2.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 16.98% to $0.39. The company's market cap stands at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 16.23% to $3.58. The company's market cap stands at $126.2 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 13.01% to $1.12. The company's market cap stands at $7.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares increased by 11.96% to $11.88. The company's market cap stands at $670.3 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares fell 52.4% to $5.08 during Thursday's pre-market session. The company's market cap stands at $98.1 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 23.08% to $1.8. The company's market cap stands at $47.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 22.77% to $4.75. The company's market cap stands at $87.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares fell 19.79% to $2.21. The company's market cap stands at $81.3 million. The company's, Q3 earnings came out today. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 18.92% to $42.0. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 17.76% to $2.78. The market value of their outstanding shares is at $32.4 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

ATXS

CLDI

FBLG

HROW

ICAD

NVCT

OPRX

PDSB

TIVC

VERO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Outperform and lowers the price target from $14 to $7.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $7

Roth MKM analyst Richard Baldry reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $20 to $16.

Reiteration

Roth MKM Reiterates Buy on OptimizeRx, Lowers Price Target to $16

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $13 to $8.

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $8

Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight and lowers the price target from $11 to $5.

Barclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $5

WIIM

OptimizeRx shares are trading lower after JMP Securities cut its price target on the stock from $16 to $8.

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and lowers the price target from $16 to $8.

JMP Securities Maintains Market Outperform on OptimizeRx, Lowers Price Target to $8

OptimizeRx shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY24 sales guidance below estimates.

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. The company reported quarterly sales of $21.309 million which missed the analyst consensus estimate of $24.997 million by 14.76 percent. This is a 30.48 percent increase over sales of $16.331 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

OptimizeRx Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $21.309M Miss $24.997M Estimate

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) sees FY2024 sales of $88.000 million-92.000 million vs $100.69 million estimate.

Guidance

OptimizeRx Sees FY2024 Sales $88.000M-92.000M vs $100.69M Est

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HYZN

IBTA

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate OptimizeRx to report an earnings per share (EPS) of $0.06.
Anticipation surrounds OptimizeRx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 5.31% drop in the share price on the subsequent day.
Here's a look at OptimizeRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.13</td>
<td>0.26</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.02</td>
<td>-0.11</td>
<td>0.26</td>
<td>0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>26.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731430913_0.png" alt="eps graph" />
<h3>Tracking OptimizeRx's Stock Performance</h3>
Shares of OptimizeRx were trading at $6.06 as of November 11. Over the last 52-week period, shares are down 39.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OPRX/earnings">To track all earnings releases for OptimizeRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: OptimizeRx's Earnings

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

EXAS

LNTH

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

The company announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over&nbsp;$10 million, which includes the previously mentioned&nbsp;$6 million&nbsp;DAAP contract.

OptimizeRx Reports Expansion Of Strategic Relationship With A Major Pharma Client

The availability of Micro-Neighborhood&#xAE; Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing &nbsp;
OptimizeRx presents panel session at Digital Pharma East: <a href="https://www.globenewswire.com/Tracker?data=tA8fr7L7-ld-_-9wCncWqKYet1Ol7b6SNxjLAGWIcKvwcp0dLLrBdptpiHgJWlAe_Q8GZOtO39Npqs6U7Ds-42asCziNzXfO-fs__vLwBCPody91dY1lKEo0nuzrEYllnUOzd1U4eOX2VPLo_2k0x85YUYFIZL6K6KY_EcwYW8uxn9pssdkhQUJTkltn7Zcajj3kri_UL8tlyaAH_B6WmVYt1KUPK5402HscogcxTkI=">Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing</a>
WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Jfzc90X4JJ4E98QXu1l9MKC1luzvAnAn2OESeY69lDmOv_BThNL8Qdt2ESFlnsGAJYfjkxiZ7dC7IHWEGa52cdX-KVrbftwIDbKI5UCR-J8=">OptimizeRx Corp</a>. (the "Company")&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and prospective patients, today announces the leading AI-driven marketing technology for healthcare consumers, Micro-Neighborhood Targeting (MNT), offered on the Company's Dynamic Audience Activation Platform (DAAP), which now further unifies outreach to patient and provider audiences via the incorporation of brand eligibility signals to consumer marketing. This enhancement to DAAP enables pharmaceutical brands to deliver synchronized, AI-guided Direct-to-Consumer (DTC) and HCP campaigns, with the mission to improve the dialogue between patients and physicians throughout the treatment journey.

OptimizeRx Launches Micro-Neighborhood Targeting, Offered On The Co's Dynamic Audience Activation Platform, Further Unifing Outreach To Patient And Provider Audiences Via The Incorporation Of Brand Eligibility Signals To Consumer Marketing

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Outperform and lowers the price target from $17 to $14.

RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $14

In the latest quarter, 5 analysts provided ratings for OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated OptimizeRx and provided 12-month price targets. The average target is $14.4, accompanied by a high estimate of $16.00 and a low estimate of $11.00. A decline of 4.0% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1723471210_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of OptimizeRx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OptimizeRx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OptimizeRx's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind OptimizeRx</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>Unraveling the Financial Story of OptimizeRx</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining OptimizeRx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.43% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -35.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OptimizeRx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.54%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.84%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.3, OptimizeRx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For OptimizeRx

Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight and lowers the price target from $15 to $11.

Barclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $11

OptimizeRx Reiterates 2024 Guidance And Expects Revenue To Be At Least $100M (Est $101.458M) With Adjusted EBITDA Of At Least $11M

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.06) by 133.33 percent. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $18.812 million which missed the analyst consensus estimate of $20.195 million by 6.85 percent. This is a 36.14 percent increase over sales of $13.818 million the same period last year.

OptimizeRx Q2 2024 Adj. EPS $0.02 Beats $(0.06) Estimate, Sales $18.812M Miss $20.195M Estimate

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – DLocal (DLO)&nbsp;up 12.3% Ta...

Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance

OptimizeRx Corporation (OPRX) Q3 2024 Earnings Call Transcript

Analyst Constantine Davides of JMP Securities maintained a Buy rating on OptimizeRx (OPRX – Research Report), reducing the price target to $8.00. C...

OptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model Shift

In a report released today, Stephanie Davis from Barclays maintained a Hold rating on OptimizeRx (OPRX – Research Report), with a price target of $...

Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (PTCT – Research Report), Medtronic (MDT – Resea...

Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)

Barclays lowered the firm's price target on OptimizeRx (OPRX) to $5 from $11 and keeps an Equal Weight rating on the shares. The stock dropped 17% ...

OptimizeRx price target lowered to $5 from $11 at Barclays

RBC Capital analyst Sean Dodge maintained a Buy rating on OptimizeRx (OPRX – Research Report) yesterday and set a price target of $7.00. The compan...

RBC Capital Reaffirms Their Buy Rating on OptimizeRx (OPRX)

Lake Street lowered the firm's price target on OptimizeRx (OPRX) to $11 from $15 and keeps a Buy rating on the shares. Revenue came in roughly $3.7...

OptimizeRx price target lowered to $11 from $15 at Lake Street

Stifel lowered the firm's price target on OptimizeRx (OPRX) to $8 from $13 and keeps a Buy rating on the shares after the company blamed its Q3 rev...

OptimizeRx price target lowered to $8 from $13 at Stifel

Roth MKM lowered the firm's price target to $16, while keeping a Buy rating on the shares as revenues miss on direct-to-consumer mix shift. Roth no...

OptimizeRx lowered to $16 at Roth MKM as revenues miss

PTCT

SONO

TARS

TTEK

Press Releases

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations

Health Care

General

OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients

OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation

OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET

OptimizeRx Reports Second Quarter 2024 Financial Results

OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences

OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value

OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET

Comments

OptimizeRx

Vendite allo scoperto

OptimizeRx (NASDAQ:OPRX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO